Aqara Launches Its First Smart Wall Switch for Europe
22.6.2021 11:00:00 EEST | Business Wire | Press release
Aqara, a provider for smart home products, announced the launch of its first smart wall switch targeted for the European market, the Aqara Smart Wall Switch H1 EU. The Wall Switch H1 EU series is Aqara’s first smart wall switch supporting both round European wall boxes and 86 mm square wall boxes. It’s available in Single and Double Rocker versions, as well as in With Neutral and No Neutral versions. Along with the Wall Switch H1 EU, Aqara also introduced the latest Wireless Remote Switch H1 (Double Rocker) to the European market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210622005459/en/
Aqara Smart Wall Switch H1 EU and Aqara Wireless Switch H1 (Photo: Aqara)
Both the Wall Switch H1 EU and the Wireless Switch H1 support the Zigbee 3.0 protocol with better stability, compatibility, responsiveness and energy efficiency1. Both switches share the award-wining design with a metal frame, which makes the switches more rigid and durable. Moreover, the combination of the Wall Switch H1 EU and the Wireless Switch H1 can be used in a 2-way switch setup without excessive wiring, or to upgrade the existing 2-way setup to a smart one, so that users will be able to control the light or other device from two different places similar to using two hard-wired 2-way switches, or even from any part of the room by voice commands or via local automations.
The Wall Switch H1 EU is compatible with major smart home ecosystems and voice assistants, including Apple HomeKit, Amazon Alexa, Google Assistant, IFTTT, and more2. The availability of With Neutral and No Neutral versions makes it fit almost all homes, while the With Neutral version supports extra features such as power monitoring and overload protection. Other features of the Wall Switch H1 EU include:
- Convert to Wireless Switch Function: The button of the switch can be remapped so that you will get an extra “wireless switch” while the light or other device will be controlled by automations;
- Overheat Protection: Users can be ensured that their homes are safe and secure;
- LED Indicator Behavior Setting: Users can configure the LED indicator via the Aqara Home app, choosing to turn it off completely, turn it on when the switch is on, or vice versa3.
The Wireless Switch H1 is a HomeKit-compatible remote switch to control Aqara devices and other HomeKit accessories or to switch between smart home scenes. It comes with a double rocker, and recognizes 7 configurable actions including single click, double click, long press, and dual-button press. It also supports the High-Speed Click Mode, which reduces the response time down to 50 milliseconds4. The Wireless Switch H1 also features a 5-year battery life, the longest so far among all Aqara battery-powered devices.
The Wall Switch H1 EU and the Wireless Switch H1 are expected to be available in various European and Asian countries via authorized Aqara distributors in the following months. Please check with your regional distributor(s) for product availability.
For more details of the Wall Switch H1 EU and the Wireless Switch H1, please visit our website.
|
1 |
A compatible Zigbee 3.0 Aqara hub (including Hub M1S, Hub M2 and Camera Hub G2H) is required. |
|
|
2 |
Integration with some third-party ecosystems may be unavailable by the time of the launch. |
|
|
3 |
Not all of these options are available for the No Neutral version. |
|
|
4 |
Only single clicks are recognized in the High-Speed Click Mode. |
About Aqara
Founded in 2016, Aqara is a leading smart home provider with offices in New York and Shenzhen. We provide comprehensive smart home products and solutions that are beautifully designed, affordable and easy to use. Our products range from a variety of sensors to switches, curtain controllers, and door locks, and we have opened more than 400 Aqara Home stores globally to provide more personalized smart home solutions.
We continue to expand our global footprint in the United States, EU, Russia, Southeast Asia, Korea and China, and our online devices have covered 192 countries and territories, serving more than 2 million customers. We aspire to bring smart home technology to every household around the world.
For more information, please visit our website and follow our social platforms.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210622005459/en/
Contact information
For Media Enquiry:
Michell Li
media@aqara.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom